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The outlook for patients with acute myocardial infarction 
has improved dramatically. During the 1960s the wide- 
spread introduction of coronary care units led to a marked 
reduction in the mortality due to primary ventricular ar- 
rhythmias. In the 1970s the use of antiarrhythmic drug 
therapy and efforts to reduce myocardial oxygen consump- 
tion with use of hemodynamic monitoring further reduced 
the risk during the acute phase of infarction (1). In the 
decade of the 1980s reperfusion therapy, predominantly 
with intravenous thrombolytic agents, was disseminated and 
a dramatic reduction in short-term and long-term mortality 
has been observed (2,3). Careful examination of these data 
has led to new questions about the mechanisms by which 
reperfusion therapy reduces mortality and about clinical 
practices that may enhance the short- and long-term effects 
of thrombolytic agents. 
Acute Reperfusion Therapy 
A carefully constructed scientific argument in favor of 
reperfusion therapy was developed from multiple experi- 
ments performed in the basic laboratory. The rationale for 
this approach was based on the demonstration that early 
reperfusion of an artery after a transient period of occlusion 
led to a smaller infarct size than that obtained with a 
permanently occluded artery (4). These experiments also 
provided important evidence that myocardial infarction 
progresses over time from the subendocardium toward the 
epicardium in a “wavefront of ischemic cell death” (5). 
Importantly, the time frame for this process in models 
thought to represent the human situation is quite short, on 
the order of 3 to 4 h. Thus, the clinical rationale for 
myocardial reperfusion was based on the concept that very 
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early reperfusion would lead to better patient outcome 
because myocardium at risk would survive. Data from 
clinical studies had demonstrated that the most powerful 
determinant of survival after acute infarction was left ven- 
tricular ejection fraction (6). Thus, shifting a patient down- 
ward on the ejection fraction curve should lead to a lower 
risk of death (Fig. 1). 
Effect on prognosis. Initial expectations that acute reper- 
fusion would alter the prognosis of patients with acute 
myocardial infarction have been met. The majority of trials 
have demonstrated a striking reduction in early mortality 
after thrombolytic therapy with streptokinase, recombinant 
tissue plasminogen activator @-PA) and anisoylated plas- 
minogen streptokinase activator complex (APSAC) (2,7-l 1). 
Furthermore, both global and regional left ventricular func- 
tion have consistently been improved in patients treated 
early with thrombolytic therapy. In patients with cardiogenic 
shock, the benefit of acute reperfusion has been dramatic 
and appears to have markedly changed the natural history of 
the syndrome (12). However, the magnitude of the effect on 
ejection fraction has been relatively small, and a consistent 
benefit has been shown only in patients treated early after 
the onset of symptoms (13-19). Furthermore, in the few 
angiographic studies that have assessed coronary patency in 
relation to mortality, the benefit occurred only in patients 
with reperfusion of the infarct-related artery: the earlier the 
artery is open, the greater the benefit to the patient (20-22). 
Mechanisms of mortality reduction. The experimental 
model of reperfusion and infarct salvage, which is sound and 
reproducible, has been supported by clinical studies and 
trials. Nonetheless, the manner in which this valid experi- 
mental postulate has been replicated in its clinical applica- 
tion is not as clear as a cursory examination of the data might 
suggest. Evidence is accumulating that the effects of reper- 
fusion in acute infarction may be the consequence of other 
mechanisms in addition to salvage of the ischemic myocar- 
dium. These possible mechanisms are listed in Table 1. 
The benefit in terms of mortality is apparent in subgroups 
of patients who achieve reperfusion at a time when myocar- 
dial salvage would not be expected. Pooled results from the 
randomized trials of intravenous thrombolytic therapy in the 
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Ejection Fraction 
Figure 1. Relation between left ventricular ejection fraction at the 
time of hospital discharge and 2 year survival after acute myocardial 
infarction. The major issue is whether thrombolytic therapy moves 
the patient to a different portion of the same curve (A) because of 
reduction of infarct size or whether reperfusion places the patient on 
a different curve that is shifted down to the left (B) by altering the 
influence of other factors on long-term survival. This figure is 
adapted with permission from Morris KG, Palmeri ST, Califf RM, et 
al. Am J Cardiol 1985;55:31&24. 
1970s (2) demonstrated a significant reduction in mortality in 
patients treated between 6 and 24 h from symptom onset. 
More recently, the ISIS 2 trial (2) found a persistent benefit 
of aspirin and streptokinase in patients treated between 6 
and 24 h after the onset of symptoms. 
It is becoming increasingly apparent that the long-term 
improvement in the outcome of patients with sustained 
patency of the infarct-related artery exceeds the expecta- 
tions based on improvement in left ventricular function 
(23-26). The Western Washington trial (20), the first to 
carefully examine long-term survival in relation to patency 
of the infarct-related artery, found improved survival at 1 
year of follow-up in patients with adequate perfusion of the 
infarct-related territory even though left ventricular function 
in the treated group was not improved over that in the 
control group. In multivariable analysis perfusion of the 
infarct-related artery was more closely related to outcome 
than was left ventricular function. 
Effect of Reperfusion on Infarct Expansion, 
Healing and Remodeling 
Infarct “remodeling” refers to the processes of early 
expansion and thinning of the infarcted segment that in turn 
(in addition to volume overload and hypertrophy) appears to 
be a major determinant of subsequent, progressive dilation 
of the noninfarcted segments of the left ventricle (27,32). The 
latter is a powerful predictor of subsequent congestive heart 
failure, ventricular arrhythmias and mortality (33,34). The 
correlation between the extent of infarct expansion and 
subsequent remodeling and infarct size is well documented, 
although the relation is widely variable (35,38). The potential 
for successful perfusion to favorably affect these pathologic 
processes is obvious. In patients entered into the TIM1 I trial 
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Figure 2. Distribution of one, two and three vessel disease in the 
Mayo Clinic series (personal communication), TIMI 2A trial (26), 
TAMI I trial (70) and Johns Hopkins series report by Schulman et al. 
(66). The proportion of patients (pts) with three vessel disease is 
significantly higher in the Johns Hopkins series. 
(39), successful reperfusion was associated with less dila- 
tion. Whether reperfusion of the infarct-related artery can 
alter the process of healing and remodeling by mechanisms 
ofher than a simple reduction in the mass of infarcted tissue 
is an important issue currently under investigation. 
Pathophysiology. In the experimental animal and in au- 
topsy studies, expansion is a function not only of infarct size 
but also of the extent of transmural necrosis. Experimental 
reperfusion has been shown to limit expansion by reducing 
the extent of transmurality, presumably by preserving an 
epicardial rim of myocardium (40,41). In a study on rats (42), 
large but only focally transmural infarcts did not show 
evidence of expansion. Hochman and Choo (43) documented 
in the rat preparation that late perfusion was associated with 
less expansion, independent of any effect on either myocar- 
dial infarct salvage or transmurality. The mechanisms 
Table 1. Possible Mechanisms for Mortality Reduction in Acute 
Myocardial Infarction After Reperfusion Therapy 
Reduction in infarct size 
Mechanical factors 
Improved healing 
Less expansion 
Less aneurysm formation (arrhythmia. thrombus) 
Lower wall stress 
Improved diastolic function 
Prevention of rupture 
Scaffolding 
Electrophysiologic function 
Arrhythmia protection 
Preservation of sympathetic fibers 
Collateral flow provision 
Ancillary therapies 
Patient selection 
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whereby this effect can be achieved are speculative and 
include the possibility that reperfusion accelerates the rate of 
healing of the infarcted segment and that the tensile strength 
and scar thickness of nonperfused and reperfused infarct 
scars are different (44-46). 
Several studies (44,47) have shown that reperfusion 
causes increased hemorrhage, cell swelling and edema 
which, by increasing the stiffness of the vessel wall, could 
reduce the extent of systolic bulging or expansion. A reduc- 
tion in diastolic infarct expansion after late reperfusion, 
unrelated to the extent of myocardial salvage, was noted by 
Force et al. (48). In contrast, however, a recent study by 
Kurnik et al. (49) showed that reperfusion reduced diastolic 
stiffness only in conjunction with an improvement in systolic 
function. 
Clinical results of reperfusion therapy. Clinical evidence 
supporting the potential for reperfusion to favorably affect 
remodeling, independent of infarct salvage, is tenuous but 
tantalizing. Jeremy et al. (50), using serum enzyme levels as 
an index of infarct size (in patients not receiving throm- 
bolytic therapy), found that the degree of perfusion of the 
infarct-related artery at predischarge angiography was an 
important predictor of subsequent left ventricular dilation, 
independent of infarct size. No such correlation was found, 
however, by Warren et al. (51) in their study of patients 
undergoing thrombolysis relatively late (5 h after the onset of 
symptoms). 
Several recent clinical studies reported in a preliminary 
fashion (52-54) offer some evidence of benefit from reperfu- 
sion independent of infarct size. Nolan et al. (52) docu- 
mented a reduction in the extent of infarct expansion after 
administration of IX-PA, even though ejection fraction and 
thallium defects were similar on day 1 in patients random- 
ized to placebo or t-t-PA. A study by Hamano et al. (54) 
documented a reduction in the development of left ventric- 
ular aneurysm, even among patients who received throm- 
bolytic therapy 4 to 10 h after the onset of symptoms. The 
possibility that reperfusion can favorably influence the heal- 
ing of the myocardial infarct, independent of the effect on 
myocardial salvage, has important implications for the tim- 
ing of treatment and size of the patient pool likely to benefit 
from reperfusion. This area remains a critical topic for 
investigation because the data to date are far from conclu- 
sive but certainly provocative. 
Marino and colleagues (54) in a report from GISSI 
(Gruppo Italian0 per lo Studio della Streptochinasi nellIn- 
farto Miocardico) in this issue of the Journal have examined 
the effects of streptokinase on preservation of cavity size 
and function, duly noting that, compared with conventional 
therapy, reperfusion therapy led to a 10% to 15% smaller 
ventricular cavity size without better ejection fraction. 
There are a few caveats to bear in mind in interpreting this 
important study. First, the improvement in regional wall 
motion, rather than reperfusion alone, likely contributed to 
preserved cavity size. Second, there was no significant 
evidence of cavity dilation between the predischarge and 6 
month evaluation. This observation differs from other pub- 
lished data (50,51) that have emphasized the occurrence of 
late cavity dilation in many patients. The lack of progressive 
dilation over time in the GISSI echocardiographic substudy 
(54) is likely due to the substantial 30% dropout rate from the 
subacute phase to follow-up, with the patients lost to follow- 
up constituting the highest risk group for further infarct 
expansion. Third, the lack of a central echocardiographic 
laboratory in this multicenter, unblinded study is conspicu- 
ous, as such a laboratory would have undoubtedly improved 
reliability and permitted more direct analysis of infarct 
expansion such as the end-systolic anterior to posterior 
endocardial segment length ratio. Fourth, there is excessive 
subgroup analysis, which predisposes toward the potential 
for spurious results. In perspective, the study provides 
further cogent evidence for an effect of reperfusion therapy 
on cavity preservation independent of functional improve- 
ment. This phenomenon is likely a key explanation for the 
discordance of mortality versus left ventricular function 
results in large scale thrombolytic trials (12,13). 
Preservation of the epicardial rim, even in the absence of 
salvage of a large amount of myocardium, may provide 
sufficient tensile strength of the infarct to prevent myocardial 
rupture. Intriguing data from another GISSI substudy (55) 
demonstrated that the risk of rupture after the first 24 h after 
treatment was markedly reduced by streptokinase therapy. 
Electrophysiologic Effects and Mortality 
The predominant mechanism of death after hospital dis- 
charge in patients treated without reperfusion therapy has 
been sudden cardiac death. Although the precise mechanism 
for such death remains unresolved, a consensus has been 
reached that patients at high risk are those with markedly 
impaired left ventricular function, multivessel coronary dis- 
ease or an unstable electrical milieu as demonstrated by 
Holter ambulatory electrocardiographic (ECG) monitoring, 
electrophysiologic study or signal-averaged ECG (56-58). 
That ischemia may precipitate the penultimate electrical 
event is suggested by the careful autopsy studies of Davies 
and Thomas (59), which documented plaque fissuring in 
patients with coronary artery disease and sudden death. 
Effect of reperfusion on arrhythmias and sudden death. 
Recent human studies have suggested that a change in the 
risk of sudden death may account for a substantial propor- 
tion of the improvement in outcome after reperfusion ther- 
apy. The first careful study implicating revascularization in 
reduction of sudden death was the multicenter Coronary 
Artery Surgery Study (CASS) (60). In this trial a profound 
effect on sudden death rates was observed in patients with 
chronic ischemic heart disease treated with coronary artery 
bypass graft surgery, particularly in patients with markedly 
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impaired rest left ventricular function. These results were 
observed despite the predominant belief at the time that 
revascularization would not help patients with “chronically 
scarred” myocardium. Although this study did not involve 
patients with acute myocardial infarction, it provided impor- 
tant clues about protection from sudden death. Subsequent 
studies (61) have demonstrated that after revascularization 
in acute myocardial infarction, abnormal afterpotentials of- 
ten return to normal on the signal-averaged ECG and fewer 
patients have prognostically important arrhythmias induced 
on electrophysiologic testing. In one interesting study (62) of 
32 patients with a large anterior wall infarction (half of whom 
had received thrombolytic therapy), incidence of inducible 
ventricular tachycardia and subsequent sudden cardiac 
death was strikingly reduced in patients treated with throm- 
bolytic therapy, despite a similar degree of left ventricular 
dysfunction. 
In a study of 62 patients by Kersschott et al. (63), 
sustained ventricular arrhythmias were less commonly in- 
duced in patients with early reperfusion after thrombolysis 
than in patients without reperfusion. This study, however, 
did not attempt to distinguish between the differential effects 
of arterial patency and ventricular function. In contrast, 
using the induction of ventricular tachycardia as a marker of 
electrical stability (rate of inducibility 22%), McComb et al. 
(64) were unable to distinguish between patients with and 
without successful reperfusion. Cardiac mortality was only 
1% in both groups over a follow-up period of 30 ? 16 
months. The conclusions of this study, regarding the effects 
of reperfusion on electrical stability must be tempered by the 
investigators’ use of antiarrhythmic therapy in patients who 
had inducible ventricular tachycardia and the relative lack of 
specificity of electrophysiologic testing when performed as 
early as 7 to 2.5 days after infarction. 
Recent observations from Cedars Sinai (65) are intriguing 
in that the strongest correlate with a persistently occluded 
infarct-related artery was the presence of late potentials, as 
assessed by the signal-averaged ECG. In a multivariable 
analysis, a powerful independent predictive variable was the 
presence of late potentials followed by the ejection fraction. 
This finding points strongly toward a beneficial effect of 
reperfusion on electrical stability in addition to the preser- 
vation of left ventricular function. 
Other Factors in Improved Mortality 
A third possible explanation is that the improved mortal- 
ity is unrelated to scar formation or the electrophysiologic 
environment. Perhaps a reduction in mortality in a subset of 
patients with ongoing ischemia accounts for all of the im- 
provement in survival in patients treated late. Perfusion of 
the infarct area could have further benefits over time engen- 
dered by the provision of collateral flow to other areas of 
myocardium when they become jeopardized. For example, a 
patient with an anterior wall infarction from left anterior 
descending artery occlusion might have a better outcome 
with subsequent right coronary occlusion if the left anterior 
descending artery was patent to provide collateral flow. 
Finally, multiple ancillary therapies in these patients, includ- 
ing beta-adenergic blockade, aspirin use and risk factor 
modification, may account for the unexpected overall reduc- 
tion in mortality and sudden death after thrombolytic ther- 
apy. 
Although the startlingly low late mortality after throm- 
bolytic therapy may be attributed to a number of potential 
pathophysiologic interactions, more mundane explanations 
need to be considered. Two critical issues are the baseline 
characteristics of patients receiving thrombolytic therapy 
and the influence of subsequent revascularization proce- 
dures. 
Role of baseline clinical characteristics. The decision to 
initiate thrombolytic therapy introduces an element of bias 
because patients over the age of 70 to 75 years have been 
excluded in most trials. Similarly, high risk patients with a 
prior history of cerebrovascular disease and other life- 
threatening conditions including gastrointestinal bleeding, 
recent cardiopulmonary resuscitation, significant hyperten- 
sion, prior coronary bypass surgery or prosthetic valve 
replacement have been excluded. 
The majority of the trials to date and all of those that have 
evaluated the role of coronary angioplasty in conjunction 
with lytic therapy required the presence of ST segment 
elevation for inclusion. The distribution of coronary artery 
disease in patients with these ECG features, however, may 
differ from that in patients presenting with ST segment 
depression. A comparison between the coronary anatomy in 
recent trials of patients undergoing thrombolytic therapy 
with that in a series of patients undergoing predischarge 
angiography at Johns Hopkins Medical School between 1974 
and 1978 highlights these differences (66). The latter patients 
did not receive thrombolytic therapy and approximately a 
third had a non-Q wave infarction. In this group, predis- 
charge angiography documented triple vessel disease in 50% 
of patients, double vessel disease in 23% and single vessel 
disease in 27%. In contrast, in the TIMI-2a (26) and TAM1 I 
(67) trials, the incidence of triple vessel disease was 11% and 
lo%, respectively, and that of double vessel disease 24% and 
32%, respectively (Fig. 2). In a Mayo Clinic series (24) of 160 
patients with acute infarction undergoing coronary angio- 
plasty with or without associated thrombolytic therapy, 
triple vessel disease was present in only 19%, double vessel 
disease in 31%, but single vessel disease in 50%. In a 
multivariable analysis of late outcome in survivors of acute 
infarction (66), the site of coronary obstruction, the number 
of vessels diseased and left ventricular function were iden- 
tified as the major determinants. 
Influence of subsequent revascularization procedures. Fi- 
nally, studies using aggressive revascularization strategies to 
1386 CALIFF ET AL. 
EDITORIAL REVIEW 
JACC Vol. 14, No. 5 
November 1, 1989:1382-S 
maintain the perfusion status of patients with clinical evi- 
dence of instability have experienced extremely low mortal- 
ity rates in long-term follow-up. Patient series from Duke 
University (23), the Mayo Clinic (24) and the University of 
Michigan (12) employing emergency angioplasty have re- 
ported extremely low mortality rates in out of hospital 
follow-up of patients discharged with a patent infarct artery. 
In the TAM1 trials (22) an intermediate strategy of rescue 
angioplasty when thrombolytic therapy failed to achieve 
patency and deferred revascularization in patients with a 
patent vessel after thrombolytic therapy resulted in similarly 
low long-term mortality rates. Preliminary results from the 
TIMI trials (25,26) have demonstrated that excellent long- 
term outcome can be achieved when angioplasty and surgi- 
cal revascularization are used liberally only in the subset of 
patients with recurrent ischemia or hemodynamic instability 
during the convalescent phase. In comparison, studies (2,3) 
with more conservative revascularization strategies have 
experienced follow-up mortality rates similar to the rates 
observed in the 1960s and 1970s. 
The high incidence of revascularization procedures (cor- 
onary bypass surgery, coronary angioplasty, or both) in 
many studies of thrombolytic therapy needs to be addressed. 
In TIMI-2a (a trial of early versus delayed angioplasty) (26) 
almost 25% of patients underwent coronary bypass surgery 
before discharge; in the TAM1 trials (68), 19% underwent 
bypass surgery before discharge and 6% during the subse- 
quent 2 years. In the Mayo Clinic series of patients under- 
going coronary angioplasty with or without lytic therapy, 
almost 30% of patients underwent coronary bypass surgery 
either before hospital discharge or during an average follow- 
up period of 2 years. Thus, the patients currently receiving 
lytic therapy appear to be a relatively low risk group, and 
many undergo coronary revascularization before discharge. 
These factors may significantly contribute to the low late 
mortality rate. 
Clinical Implications 
If the benefits of reperfusion occur for reasons beyond the 
traditional model of acute myocardial salvage, the implica- 
tions for current treatment and development of future treat- 
ment strategies are profound. Many of the recommendations 
for current therapy are based on the concept that treatment 
should be limited to patients in whom infarction is not 
“complete,” although the definition of the term “complete” 
is not as clear as previously assumed. Development of 
risk/benefit models based solely on changes in left ventricu- 
lar function as characterized by ejection fraction would lack 
a significant component reflecting other effects of an open 
infarct-related artery. A broader spectrum of patients would 
need to be treated and more effective methods of achieving 
and sustaining myocardial salvage would be needed so that 
the 10% to 25% of patients currently discharged from the 
hospital with a closed infarct-related artery despite throm- 
bolytic therapy would not be deprived of the benefits of 
persistent perfusion. Better definition of other factors relat- 
ing to scar formation and the potential for an arrhythmogenic 
substrate is needed. 
An important patient group in which these concepts can 
be explored comes to medical attention after the infarct is 
“complete” by the traditional definition of symptom onset 
>6 hours, Q wave formation and resolution of symptoms. If 
reperfusion in these patients results in better outcome, then 
the contribution of other factors can be examined in the 
absence of the confounding effect of myocardial salvage. 
Confirmation of a benefit might lead to a multifaceted 
approach to the treatment of acute myocardial infarction that 
would seek to obtain early perfusion for myocardial tissue 
salvage and persistent reperfusion together with careful 
control of the hemodynamic state to achieve myocardial 
shape salvage and a favorable electrophysiologic substrate. 
Conclusion 
The concept of acute reperfusion in evolving myocardial 
infarction has motivated an exciting era of investigation with 
demonstrable success in the clinical arena. The initial results 
of this therapeutic approach have fulfilled its promise and 
further advances in management are forthcoming. An im- 
proved understanding of the complexity of the effects of 
reperfusion therapy has unveiled the potential for further 
benefits aside from salvage of ischemic myocardium. These 
findings provide an exciting challenge to reach the goal of 
increased patient salvage in addition to myocardial salvage. 
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